skip to main content

Levetiracetam Preference in Palliative Care — SCE Palliative Medicine MCQ

Instant feedback + full explanation. One question, done properly.

ModeratePain ManagementLevetiracetam Preference in Palliative CareSCE Palliative Medicine

A 70‑year‑old man with advanced prostate cancer and known brain metastases develops new‑onset seizures. He is started on levetiracetam 500 mg twice daily. He is also receiving dexamethasone, strong opioids, anticoagulation, and other palliative medications. Why is levetiracetam preferred over phenytoin or carbamazepine in this palliative care context?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Levetiracetam has minimal drug interactions, requires no serum‑level monitoring due to linear pharmacokinetics, and is available in oral, IV and subcutaneous formulations to support route changes

Explanation lettering: E = shown as C · C = shown as D · D = shown as E

Option E is the only defensible choice. In UK palliative care, levetiracetam is preferred because it does not induce hepatic enzymes and therefore has minimal interaction risk, including with dexamethasone and other polypharmacy common in this setting. It has linear pharmacokinetics and does not require therapeutic‐level monitoring. Crucially, it can be administered via multiple routes (oral, IV, subcutaneous/CSCI) without dose change, facilitating seamless care as swallowing deteriorates. Other options are incorrect: efficacy is broadly comparable (A), aesthetic effects are irrelevant (B), enzyme‐inducing AEDs are not absolutely contraindicated with steroids (C), and other agents (e.g. phenytoin) do have IV formulations (D).

Reference: Scottish Palliative Care Guidelines: Seizures – Right Decisions (NHS Scotland); Greater Manchester & Eastern Cheshire Palliative Care Pain & Symptom Control Guidelines (2026)